Because favorable CDDP pharmacokinetics suggest the potential for enhanced CDDP tumoricidal effect during CHPP, tumor debulking and CHPP may represent an effective strategy for the treatment of peritoneal mesothelioma. I TI - Cloning and expression of the recombinant FAb fragment of monoclonal antibody K1 that reacts with mesothelin present on mesotheliomas and ovarian cancers. Recombinant FAb was produced in Escherichia coli in inclusion bodies that were solubiliz- ed and refolded to active protein. The cloned FAb can be used to make higher affinity antibodies and immunoconjugates that could be useful for various types of immunotherapies. A phase II trial demonstrating activity accompanied by cardiac toxicity.
Malignant mesothelioma is a disease that is refractory to chemotherapy.
One patient had a complete response, two had objective partial responses, and four had regression of evaluable disease. The one complete responder remains without disease progression at 6 years. Chest pain and nausea were the most common toxicities. In most patients, gastrointestinal effects were manageable. There was no significant hematologic toxicity.